|
Meta-analysis of upfront VEGF targeted therapy prior to nephrectomy in metastatic clear cell renal cancer. |
|
Akhila Ganeshi Wimalasingham |
No Relationships to Disclose |
|
Alfonso Gomez De Liano Lista |
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); MSD Oncology (Inst); Neon Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst) |
Research Funding - Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); MSD (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Lilly (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst) |
Research Funding - Bristol-Myers Squibb |
Travel, Accommodations, Expenses - Pfizer |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Genentech/Roche; Merck; Novartis |
Research Funding - AstraZeneca/MedImmune; Roche/Genentech |
|
|
No Relationships to Disclose |